Comparative Pharmacology
Head-to-head clinical analysis: STALEVO 150 versus STALEVO 50.
Peer-Reviewed Evidence
Head-to-head clinical analysis: STALEVO 150 versus STALEVO 50.
STALEVO 150 vs STALEVO 50
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Stalevo 150 is a combination of carbidopa, levodopa, and entacapone. Levodopa is converted to dopamine in the brain, replenishing striatal dopamine levels. Carbidopa inhibits peripheral decarboxylation of levodopa, increasing its bioavailability. Entacapone is a selective and reversible inhibitor of catechol-O-methyltransferase (COMT), reducing peripheral metabolism of levodopa to 3-O-methyldopa.
Stalevo 50 is a combination of carbidopa, levodopa, and entacapone. Levodopa is converted to dopamine in the brain, replenishing striatal dopamine levels. Carbidopa inhibits peripheral decarboxylation of levodopa, increasing its central availability. Entacapone is a selective, reversible inhibitor of catechol-O-methyltransferase (COMT), reducing peripheral metabolism of levodopa to 3-O-methyldopa, thereby prolonging its half-life.
One tablet orally three times daily. Each tablet contains 150 mg levodopa, 37.5 mg carbidopa, and 200 mg entacapone.
One tablet (carbidopa 12.5 mg, levodopa 50 mg, entacapone 200 mg) orally, up to 8 tablets per day in divided doses, adjusting based on individual response. Maximum levodopa dose: 800 mg/day.
None Documented
None Documented
Levodopa (with carbidopa): ~1.5-2 hours. Carbidopa: ~1-2 hours. Entacapone: ~0.4-0.7 hours (short half-life; not primary determinant of dosing interval). Clinically, levodopa half-life determines dosing frequency for motor fluctuations.
Levodopa: 1-3 hours (short half-life necessitates frequent dosing; COMT inhibition by entacapone prolongs elimination half-life by ~1-2 hours vs levodopa alone). Carbidopa: 1-2 hours. Entacapone: 0.4-0.7 hours (terminal half-life in plasma).
Carbidopa and levodopa are primarily excreted renally. Levodopa: ~70-80% renal, with metabolites including 3-O-methyldopa. Carbidopa: ~50-70% renal, with ~30% fecal. Entacapone: ~90% fecal (mainly as metabolites), ~10% renal.
Renal: ~80% (carbidopa: 70% unchanged, levodopa metabolites: 70-80% as HVA/DOPAC); Fecal: ~20% (entacapone: primarily as glucuronide conjugates via bile).
Category C
Category C
Anti-Parkinson Agent
Anti-Parkinson Agent